← Research
research published 2024-11-01 · by Abud-Mendoza C, Alpizar-Rodriguez D, Alvarez-Nemegyei J, Amaya-Estrada JL, Amigo-Castañeda MC, Andrade-Ortega L, Barile-Fabris LA, Barragán-Navarro YR, Carrillo-Vázquez SM, Castro-Colín Z, Cruz-Álvarez LJ, de Anda KS, Durán-Barragán S, Esquivel-Valerio JA, Fragoso-Loyo H, Galarza-Delgado DA, Gamez-Nava JI, García-García C, Gonzalez-Lopez L, Gordillo-Huerta MV, Hadid-Smeke J, Hernández-Bedolla A, Hernández-Cabrera MF, Herrera-VanOostdam DA, Horta-Baas G, Irazoque-Palazuelos F, Iturbide-Escamilla AE, Jara-Quezada LJ, Merayo-Chalico J, Muñoz-Lopez S, Pacheco-Tena C, Pérez-Cristóbal M, Pimentel-Leon RR, Pinto-Ortiz M, Portela-Hernández M, Ramos-Sánchez MA, Saavedra MÁ, Sandoval-Cabrera DV, Sicsik-Ayala S, Silveira LH, Xibillé-Friedmann D
Reumatologia clinica · 2024 Nov
PubMed #39505612
Abstract
Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system. We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.
Neurotransmitters
None linked yet.
Ratings (0): Breadth — · Depth — · Enjoyment
— · Usefulness —
Community
Log in to rate and share your notes.
No contributions yet.